Drug intelligence / Profile preview

compound tripeptide

Development stage: Preclinical
Lead developer: Eli Lilly
Modality: Peptides
Administration: Injection

Overview

Compound tripeptide is a pharmaceutical agent administered via injection, currently under investigation for its potential to treat peripheral neurotoxicity. It is being studied in combination with Wenluotong lotion as a treatment for peripheral neurotoxicity induced by TP chemotherapy regimens in patients with tumors. The specific mechanism of action and detailed chemical composition are not provided in the available context.

Beyond the preview

Go deeper on compound tripeptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on compound tripeptide.

Explore the full profile